177 related articles for article (PubMed ID: 19583718)
1. Blue-sky thinking about blue-light cystoscopy.
Thomas K; O'Brien T
BJU Int; 2009 Oct; 104(7):887-9. PubMed ID: 19583718
[No Abstract] [Full Text] [Related]
2. Improved detection and reduced early recurrence of non-muscle-invasive bladder cancer using hexaminolaevulinate fluorescence cystoscopy: results of a multicentre prospective randomized study (PC B305).
Mostafid H; Bunce C;
BJU Int; 2009 Oct; 104(7):889-90. PubMed ID: 19549121
[No Abstract] [Full Text] [Related]
3. The role of hexylaminolaevulinate in the diagnosis and follow-up of non-muscle-invasive bladder cancer.
Bunce C; Ayres BE; Griffiths TR; Mostafid H; Kelly J; Persad R; Kockelbergh R
BJU Int; 2010 Feb; 105 Suppl 2():2-7. PubMed ID: 20089091
[No Abstract] [Full Text] [Related]
4. Editorial comment.
Scarpa RM; Cracco CM
Urology; 2009 Dec; 74(6):1286-7; author reply 1287-8. PubMed ID: 19962530
[No Abstract] [Full Text] [Related]
5. [Fluorescence diagnosis and photodynamic therapy in urology].
Stepp H; Waidelich R
Aktuelle Urol; 2007 Nov; 38(6):455-64. PubMed ID: 17987533
[TBL] [Abstract][Full Text] [Related]
6. Hexylaminolaevulinate 'blue light' fluorescence cystoscopy in the investigation of clinically unconfirmed positive urine cytology.
Ray ER; Chatterton K; Khan MS; Thomas K; Chandra A; O'Brien TS
BJU Int; 2009 May; 103(10):1363-7. PubMed ID: 19076151
[TBL] [Abstract][Full Text] [Related]
7. [Clinical significance of macroscopic 5-aminolevulinic acid (ALA)-inducer fluorescence in transurethral resection of non-invasive bladder cancer].
Danil'chenko DI; Koenig F; Riedl K; Schnorr D; Waldman A; Al-Shukri S; Loening SA
Vopr Onkol; 2003; 49(6):734-7. PubMed ID: 14976918
[TBL] [Abstract][Full Text] [Related]
8. Quantification of 5-aminolevulinic acid induced fluorescence improves the specificity of bladder cancer detection.
Zaak D; Frimberger D; Stepp H; Wagner S; Baumgartner R; Schneede P; Siebels M; Knüchel R; Kriegmair M; Hofstetter A
J Urol; 2001 Nov; 166(5):1665-8; discussion 1668-9. PubMed ID: 11586198
[TBL] [Abstract][Full Text] [Related]
9. Hexylaminolaevulinate fluorescence cystoscopy in patients previously treated with intravesical bacille Calmette-Guérin.
Ray ER; Chatterton K; Khan MS; Chandra A; Thomas K; Dasgupta P; O'Brien TS
BJU Int; 2010 Mar; 105(6):789-94. PubMed ID: 19832725
[TBL] [Abstract][Full Text] [Related]
10. 5-aminolaevulinic acid-induced fluorescence cystoscopy during transurethral resection reduces the risk of recurrence in stage Ta/T1 bladder cancer.
Babjuk M; Soukup V; Petrík R; Jirsa M; Dvorácek J
BJU Int; 2005 Oct; 96(6):798-802. PubMed ID: 16153204
[TBL] [Abstract][Full Text] [Related]
11. Hexyl aminolevulinate fluorescence cystoscopy in bladder cancer.
Sievert KD; Kruck S
Expert Rev Anticancer Ther; 2009 Aug; 9(8):1055-63. PubMed ID: 19671025
[TBL] [Abstract][Full Text] [Related]
12. [The impact of ALA (5-aminolevulinic acid)-fluorescence detection on the prognosis of superficial bladder cancer].
Daniltchenko D; Riedl C; Koenig F; Daha LK; Sachs M; Schnorr D
Aktuelle Urol; 2004 Nov; 35(6):497-501. PubMed ID: 15526230
[TBL] [Abstract][Full Text] [Related]
13. Blue light cystoscopy for detection and treatment of non-muscle invasive bladder cancer.
Mark JR; Gelpi-Hammerschmidt F; Trabulsi EJ; Gomella LG
Can J Urol; 2012 Apr; 19(2):6227-31. PubMed ID: 22512972
[TBL] [Abstract][Full Text] [Related]
14. Hexaminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: review of the evidence and recommendations.
Witjes JA; Redorta JP; Jacqmin D; Sofras F; Malmström PU; Riedl C; Jocham D; Conti G; Montorsi F; Arentsen HC; Zaak D; Mostafid AH; Babjuk M
Eur Urol; 2010 Apr; 57(4):607-14. PubMed ID: 20116164
[TBL] [Abstract][Full Text] [Related]
15. [Role of fluorescent control in raising radicality of surgical treatment for superficial bladder cancer].
Matveev BP; Kudashev BV; Bukharkin BV; Romanov VA; Rubanov IuV
Urologiia; 2000; (3):22-4. PubMed ID: 11186703
[TBL] [Abstract][Full Text] [Related]
16. Role of hexaminolevulinate-guided fluorescence cystoscopy in bladder cancer: critical analysis of the latest data and European guidance.
Malmström PU; Grabe M; Haug ES; Hellström P; Hermann GG; Mogensen K; Raitanen M; Wahlqvist R
Scand J Urol Nephrol; 2012 Apr; 46(2):108-16. PubMed ID: 22087730
[TBL] [Abstract][Full Text] [Related]
17. Clinically relevant reduction in risk of recurrence of superficial bladder cancer using 5-aminolevulinic acid-induced fluorescence diagnosis: 8-year results of prospective randomized study.
Denzinger S; Burger M; Walter B; Knuechel R; Roessler W; Wieland WF; Filbeck T
Urology; 2007 Apr; 69(4):675-9. PubMed ID: 17445650
[TBL] [Abstract][Full Text] [Related]
18. Hexaminolevulinate blue light cystoscopy: a review of its use in the diagnosis of bladder cancer.
Yang LP
Mol Diagn Ther; 2014 Feb; 18(1):105-16. PubMed ID: 24248555
[TBL] [Abstract][Full Text] [Related]
19. Diagnosis of urothelial carcinoma of the bladder using fluorescence endoscopy.
Zaak D; Karl A; Knüchel R; Stepp H; Hartmann A; Reich O; Bachmann A; Siebels M; Popken G; Stief C
BJU Int; 2005 Aug; 96(2):217-22. PubMed ID: 16001963
[TBL] [Abstract][Full Text] [Related]
20. Improved detection and treatment of bladder cancer using hexaminolevulinate imaging: a prospective, phase III multicenter study.
Jocham D; Witjes F; Wagner S; Zeylemaker B; van Moorselaar J; Grimm MO; Muschter R; Popken G; König F; Knüchel R; Kurth KH
J Urol; 2005 Sep; 174(3):862-6; discussion 866. PubMed ID: 16093971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
